A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
UNLABELLED: The recent identification of liver-expressed antimicrobial peptide 2 (LEAP2) as an endogenous antagonist and inverse agonist of the growth hormone secretagogue receptor (GHSR) has revived interest in targeting the ghrelin-GHSR pathway for…
AIM: This meta-analysis aims to evaluate the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RAs), on new-onset atrial fibrillation (AF) in randomized clinical trials (RCTs). METHODS AND RESULTS: Twenty-six RCTs involving 48,…
AIMS: As a result of the withdrawal of lorcaserin and the approval of tirzepatide and semaglutide, we conducted a new network meta-analysis to assess the overall and comparative effects of six US Food and Drug Administration (FDA)-approved weight-los…
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an important therapeutic option for type 2 diabetes mellitus (T2DM), available in both oral and subcutaneous formulations. While subcutaneous semaglutide has been availab…
BACKGROUND: Obesity is a chronic medical condition with a rising prevalence in the United States. A wide range of morbidity and mortality is associated with obesity, with coronary artery disease being among the most common. Ischemic heart disease con…
Circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) are promising markers of vascular damage and endothelial regeneration potential. We focused on the detection of CECs and EPCs using flow cytometry with regard to analytical…
PURPOSE: Dry eye disease (DED) is a prevalent ocular surface disorder frequently associated with type 2 diabetes mellitus (T2DM). While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated systemic anti-inflammatory and vascular be…
Semaglutide (Ozempic®), administered as a weekly subcutaneous injection up to 1.0 mg, holds a privileged place in the international guidelines for the management of type 2 diabetes. Commercialized under the trade name Wegovy®, semaglutide is also ind…
BACKGROUND: Classic congenital adrenal hyperplasia, primarily due to 21-hydroxylase deficiency, leads to impaired cortisol and aldosterone production and excess adrenal androgens. Lifelong glucocorticoid therapy is required, often necessitating supra…
Glucagon-like peptide-1 receptor agonist (GLP1a) agonists are one of the most recent discoveries to improve blood glucose control and provide satiety. The U.S. Food and Drug Administration (FDA) approved the first of these therapeutics for the manage…
BACKGROUND: The rising obesity rates in the USA have led to a surge in various weight loss treatments. Glucagon-like peptide-1 (GLP-1) analogues have shown promise in reducing weight but primarily studied in Caucasian populations. Sleeve gastrectomy…
PURPOSE: The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications are widely prescribed for management of diabetes mellitus as well as obesity or weight management. Although there have been rare reports of skin hypersensitivity ass…
BACKGROUNDDespite growing preclinical evidence that glucagon-like peptide1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl peptidase-4…
Semaglutide is a GLP-1 receptor agonist that is highly efficacious in reducing food intake and body weight. While semaglutide reduces adipose tissue, there is also a loss of lean mass including skeletal muscle, though it is unclear whether this trans…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely accepted for managing Type 2 diabetes mellitus. However, numerous drug-related problems (DRPs) have recently been reported about GLP-1 RAs. OBJECTIVES: The present descripti…
OBJECTIVE: GLP-1 receptor agonists (GLP-1 RAs) reduce cardiovascular events in type 2 diabetes (T2D), and oral formulations improve accessibility. However, their real-world effectiveness and predictors of response remain unclear. This study assessed…
Neuronal injury is a common complication in patients with diabetes. These injuries include a wide range of neurobehavioral complications that significantly reduce the neuronal network efficiency and quality of life in affected individuals. Currently,…
BACKGROUND: Obesity is well-established risk factor of heart failure (HF); however, "obesity paradox" has been described in symptomatic HF patients. The STEP-HFpEF study suggested that once-weekly subcutaneous semaglutide might improve outcomes in pa…